key: cord-1051371-y1zqk462 authors: Hazra, Suvojit; Chaudhuri, Alok Ghosh; Tiwary, Basant K.; Chakrabarti, Nilkanta title: Candidate genes associated with neurological manifestations of COVID-19: Meta-analysis using multiple computational approaches date: 2022-04-11 journal: bioRxiv DOI: 10.1101/2022.04.10.487761 sha: b616732940340becf94321c8f97cc427d7c26b1d doc_id: 1051371 cord_uid: y1zqk462 COVID-19 develops certain neurological symptoms, the molecular pathophysiology of which is obscure. In the present study, two networks were constructed and their hub-bottleneck and driver nodes were evaluated to consider them as ‘target genes’ followed by identifying ‘candidate genes’ and their associations with neurological phenotypes of COVID-19. A tripartite network was first constructed using literature-based neurological symptoms of COVID-19 as input. The target genes evaluated therefrom were then used as query genes to identify the co-expressed genes from the RNA-sequence data of the frontal cortex of COVID-19 patients using pair-wise mutual information to genes. A ‘combined gene network’ (CGN) was constructed with 189 genes selected from TN and 225 genes co-expressed in COVID-19. Total 44 ‘target genes’ evaluated from both networks and their connecting genes in respective networks were analyzed functionally by measuring pair-wise ‘semantic similarity scores’ (SSS) and finding Enrichr annotation terms against a set of genes. A new integrated ‘weighted harmonic mean score’ was formulated using SSS and STRING-based ‘combined score’ to select 21 gene-pairs among ‘target genes’ that provided 21 ‘candidate genes’ with their properties as ‘indispensable driver nodes’ of CGN. Finally, six pairs providing seven prevalent candidate genes (ADAM10, ADAM17, AKT1, CTNNB1, ESR1, PIK3CA, FGFR1) exhibited direct linkage with the neurological phenotypes under tumour/cancer, cellular signalling, neurodegeneration and neurodevelopmental diseases. The other phenotypes under behaviour/cognitive and motor dysfunctions showed indirect associations with the former genes through other candidate genes. The pathophysiology of ‘prevalent candidate genes’ has been discussed for better interpretation of neurological manifestation in COVID-19. The 'coronavirus disease 2019' patients present common symptomatic features of dry cough, dyspnea, fever, fatigue and myalgia 1,2 followed by the acute respiratory distress syndrome (ARDS) in an advanced stage 3 . The COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the genera of β-coronavirus having positive single-stranded RNA as its genome [3] [4] [5] [6] . The SARS-CoV-2 can infect a wide variety of human tissue cells, leading to a greater viral load resulting in a multiorgan failure. The pathophysiological action of the virus always begins with the binding of spike proteins onto the angiotensin-converting enzyme 2 (ACE2) receptor proteins in the host cell membranes and expresses several phenotypic manifestations in human 7, 8 . The human ACE2 receptors are constitutively expressed in neurons, pericytes and endothelial cells of the olfactory bulb and certain neuroglial cells like astrocytes and oligodendrocytes. Neuromodulator regions of dopaminergic, serotoninergic, histaminergic and norepinephrinergic nuclei and several specific brain regions including substantia nigra and piriform cortex, are also rich in ACE2 receptors. Relatively, a greater expression of ACE2 receptors is evident in the brain stem, central glial substance and choroid plexuses of lateral ventricles of the brain9. The ACE2 levels were found to be very low in the human prefrontal cortex and hippocampus 9 . COVID-19 is reported to associate with lesions in the hippocampus 10 and frontal cortex 11 and, the structural changes in the brain stem, medulla and pons 12 . The SARS-CoV-2 RNA has also been detected in the medulla and cerebellum through an RT-PCR study that represented contamination in the leptomeninges and Virchow-Robin spaces (perivascular space) 13 . The SARS-CoV-2 can enter the brain through three possible pathways via (i) the inflammatory supporting cells of the olfactory mucosa 13 , (ii) the endothelial cells of the cerebral blood vessels 14, 15 and (iii) the nerve terminals of the vagi in the respiratory 14, 15 and gastrointestinal tracts. SARS-CoV-2 was found to be present in the cerebrospinal fluid (CSF) of patients suggesting the predominance of immunological damages over the viral replication in neurons 16 . Among the three pathways, the first one appears to be the The TN of symptom-disease-gene (nodes) was constructed using connections (edges) developed by mathematical and statistical formulations. The stepwise approach for construction of TN is presented in the pictorial diagram (Fig. 2) . The terms or keywords of neurological symptoms (represented by nodes) related to COVID-19 were found by systematic PubMed bibliographic literature search. Initially, the symptom-based disease and gene bipartite (symptom-disease and symptom-gene) networks were constructed by generating a corpus of data using Human Phenotype Ontology (HPO) 51 , a comprehensive digital vocabulary database of disease associated phenotype information including genomic interpretation of diseases. The bipartite networks were constructed providing weightage to each symptom i.e., 'bibliographic keyword citation frequency' (fbkc(Si)) as the count of appearance of a keyword/term in an article set 52 and assigning its connectivity (Nsd(Si) or Nsg(Si)) probability score to diseases (fbkc(Si)/Nsd(Si)) and genes (fbkc(Si)/ Nsg(Si)) considering co-occurrence of at least one disease/gene connection to one symptom term following the principle of frequency of the co-occurrence of root node in the directed acyclic graph 53 . The false discovery rate (FDR)-adjusted p<0.001 was used to filter connections in both symptomdisease and symptom-gene bipartite network. The new approach was implemented to find disease-gene interactions using selected diseases and genes found in bipartite networks. The Malacards 54 , a comprehensive integrated database of human maladies and their annotations including genetic entities, was mined to find the Elite disease-gene interactions with scores (Sorl's relevance score) as the strength of their interactions. In addition, the integrated symptom-based weightage (Wd(Di)) of diseases was generated (point-5 of Fig. 2 ) which were multiplied by respective Malacards-scores to get disease-gene 'integrated connection scores' followed by calculating their average to get weightage of a gene (Wg(gi)) considering co-occurrence of at least connections of one disease to one symptom and one gene term in the network (point-6 of Fig. 2 ). The weightage (Wd(Di)) of a disease was calculated by dividing the average of 'connection probability score' (fbkc(si)/Nsd(si)) of symptoms to a disease by the summation of the frequency of connections (point-5 of Fig. 2) . The FDR-adjusted p<0.01 was used to filter disease-gene connections and a tripartite network (TN) was formed. The intra-connectivity of nodes within tripartite network was further filtered by using cosine semantic similarity scores ≥ 0.70 for retaining symptom-symptom and disease-disease pairs. The pairwise cosine semantic similarity between symptoms were calculated 55 as considering each symptom node as vector of connected diseases and vice versa for disease-disease cosine similarity calculation by considering each disease node as a vector of connected symptoms. The gene-gene intra-connectivity were filtered by using STRING 56 confidence score ≥ 0.70 to get the final TN. The topology analysis of the TN was done in Cytoscape software 57 using the CentiScaPe module 58 to find 'target nodes' (hub-bottleneck and driver nodes) for symptoms, diseases and genes. The important nodes (Hub-bottlenecks and driver nodes) evaluated from TN were considered as co-regulated in tissue and used as query genes to identify a set of coexpressed genes from RNA-Seq data 59 (NCBI-GEO accession ID: GSE164332) of brain frontal cortex of COVID-19 patients (n=9) with healthy matched controls (n=7), using geneRecommender algorithm 60,61 in R software and environment. In this algorithm, the count data of the RNA-Seq samples of the input dataset for gene co-expression study was first normalized, then cross-validation was performed by leave-one-out method and genes were finally ranked based upon Spearman correlation with query genes using Zscore. The co-expressed genes were selected using minet package 62 in R-language based on algorithm for ARACNe (Algorithm for the Reconstruction of Accurate Cellular Networks) 63 assigning weights of (a) pair-wise mutual information (transcriptional genegene interaction from expression levels) to genes as nodes and (b) empirical probability (entropy estimators) to its edge with given threshold value for refining node-pairs. A combined set of 225 genes collected from minet output (co-expressed genes) and all 189 genes of TN, were incorporated as a query in STRING database 56 using 'STRING-PPI combined score' (SPPICS) 0.60 as threshold, to construct a PPI-based 'combined gene network' (CGN). The study was further extended to construct networks using three other different 'SPPICS' viz. 0.70, 0.80 and 0.90 as thresholds in respective cases. The CGNs were incorporated separately into the Cytoscape software 57 to find HB and driver nodes for each network using the CentiScaPe module 58 . The HB and driver nodes were cumulated from four CGNs termed as second set of 'target genes' evaluated from CGN. The centrality measurements of networks were analyzed using the CentiScaPe module 58 in Cytoscape software 57 to find 'hub' (high degree) and 'bottleneck' (highbetweenness/shortest-path) nodes that having higher scores than cut-off values i.e., respective average node degree and average node betweenness scores (for TN: 18 [64] [65] [66] [67] . The controllability measurements of two networks were analyzed by finding 'driver nodes' using the Minimum Driver node Set (MDS) algorithm from the CytoCtrlAnalyser 68 module of Cytoscape software. The driver nodes are the minimum number of nodes in a network which control all nodes by receiving the input signals and provide the controllability measurements to analyze the temporal (dynamic) properties of a complex network 69, 70 . Driver nodes are classified into three categories based on the impact of the nodes on controlling main network viz. (a) 'indispensable' i.e., positive control factor, the removal of which increases the total driver nodes in main network, (b) 'dispensable' i.e., negative control factor, the removal of which decreases the total driver nodes in main network and (c) 'neutral' control factor the removal of which does not change total driver nodes in main network 69, 71 . In the present study, the finally selected 'candidate genes' were drawn from CGN (combined gene network) by leave-one-out method to cross-validate the control property ('indispensable'/'dispensable'/'neutral') of the nodes on the CGN by measuring the % changes of driver nodes (total and pure driver) after removal of the specific 'candidate genes'. The pure driver nodes were designated as driver nodes without having hub-bottleneck properties. The nodes having high centrality (hub with bottleneck properties) as well as controllability (driver property) values were supposed to be the disease candidates 69, 72 and therefore termed those selected nodes as 'target symptoms', 'target disease' and 'target genes' (TG-TN) of COVID-19 evaluated from TN. In parallel, the 'target genes' (TG-CGN) of COVID-19 were also evaluated from CGN. The functional associations among 'target nodes' were analyzed by semantic comparison of Gene Ontology (GO) terms 73, 74 quantitatively through computing similarities between gene-pairs and also clustering gene-pairs into known pathways. In this regard, the Wang's GO-BP (biological process) 'semantic similarity score' (SSS) had been measured using GOSemSim package 75 in R-language using best-match average (BMA) combination strategy to get the results closer to human expectations 76, 77 . The SSS measurements were performed in two functions 75 namely, (a) 'mgeneSim' and (b) 'mclusterSim' that estimated pairwise semantic similarities for a list of gene and 'geneclusters', respectively. A 'gene-cluster' represented the modular nature of connected gene-set that resorted the annotation similarity network of the gene-set to prioritize the connected genes against a 'target node'. Therefore, the SSS measured in two ways (a) 'direct association', designated as SSS-I, by the comparative assessment of associated GO-BP terms of each of two genes and (b) 'indirect association', designated as SSS-II, to represent the summated contribution of comparative assessment of associated GO-BP terms of gene-clusters against targeted gene-pairs. Notably, SSS-I and SSS-II were measured for 'target genes' evaluated from both TN and CGN. The pair-wise SSS (SSS-II) for 'target diseases' was measured based on their connecting 'gene-clusters' in the TN using mclusterSim function in GOSemSim package 75 following the top-down disease module approach 48 whereby the inference of diseasedisease association was drawn based on underlying molecular mechanism. The similar approach was used for finding pair-wise SSS for 'target symptoms' found in the TN. Further, the classifier statistics ROC-AUC was introduced using pROC package 78 in R software and environment to filter out spurious pair-wise SSSs for symptom-, diseaseand gene considering the accuracy classification as excellent (0.9 < AUC < 1.0), good (0.8 < AUC < 0.9) and weak (AUC <0.8). The optimal threshold for ROC based on optimum F1 score and maximum accuracy was considered as cut-off value for selection of gene-pairs among 'target nodes' for finding 'candidate nodes' for symptoms, diseases and genes. 79, 80 , an intuitive web-tool for gene over-representation study with an inclusive functional annotation set, by considering each gene-set as query. FDR-adjusted p-value less than 0.05 related to nervous system were considered as significantly enriched term. In the present study, the Set-2 and Set-4 gene-sets were pondered to double-check the over-represented functional annotation of respective Set-1 and Set-3 gene-sets. The pairwise SSS-II scores for statistically confident enriched terms were calculated using mclusterSim function in GOSemSim package 75 as previously described methods. The functional annotation terms for 'candidate genes' were manually curated from integrated Enrichr results and were further analyzed for the pairwise SSS-II scores to find statistically confident enriched terms using mclusterSim function in GOSemSim package as previously described methods. The classifier statistics ROC-AUC was used to find accurate classification based on AUC values and select functionally associated Enrichr terms based on the optimal threshold for ROC as cut-off of SSS-II scores. The integrated 'weighted harmonic mean score' (WHMS) were evaluated using harmonic mean of weightage scores for gene-pairs among 'target genes' which appeared to fulfil The classifier statistics ROC-AUC and the optimal threshold for ROC as cut-off of WHMS were utilized to obtain the prevalent 'candidate gene-pairs' considering them as putative disease associated genes. The results found in the present meta-analysis of the rapport of brain disease related phenotypes and molecular machineries involving genes/proteins were systematically documented in the flow diagram with the findings of prevalent 'candidate genes' and their links with neurological functional modules in COVID-19 ( Fig. 1 ). Among 255 symptoms of COVID-19 patients obtained from 103 selected articles under Fig. 3d and 3E) and 'pure driver' nodes (10 genes mentioned in Fig. 3d and Fig. 3e ). The 27 'target genes' (nodes with properties of 'both HB and driver', 'pure driver', 'pure HB') evaluated from TN used as query genes against a set of 38306 genes from RNA-Seq data of brain frontal cortex of COVID-19 patients in geneRecommender analysis and identified that 10913 genes (28.48% of total genes) ranked (functionally correlated to query genes) as co-expressed genes (CG) with the set of 14 query genes (marked '*' in The total 414 genes including the exclusive 225 co-expressed genes of minet output and 189 genes including 27 'target genes' found in TN were used as input for STRING database and provided a PPI (Protein-Protein Interaction) network (network density 0.010, average clustering co-efficient 0.169) which was designated as 'combined gene network' (CGN) of 281 gene nodes, using SPPICS confidence threshold values >0.60. ( Fig. 4b) The study was extended to construct STRING-PPI networks using same set of genes as input with different SPPICS confidence threshold score viz. >0. 70 The 73 symptoms and 47 diseases as 'target nodes' evaluated from TN, provided pairwise SSS-II scores for 2628 ( 73 C2) and 1081 ( 47 C2) combinations ( Fig. 3b and Fig. 3c ). The 45.53% symptom-pairs and 12.01% diseases-pair had been found significant based on the 'optimal threshold for ROC' as cut-off values. The categorical investigation of filtered symptom-pairs resulted 22.42% intra-group and 77.57% inter-group connections including the categories (%inter:%intra) under (i) general The 27 TG-TN showed 351 ( 27 C2) . 3a and 4b) . Therefore, total 21 gene-pairs including eight from TN, 12 from CGN and one common for both TN and CGN found to have SSS-I, SSS-II and SPPICS values and, were designated as 'candidate gene pairs' for COVID-19 (Fig. 5f ). (Table 1) . Enrichr annotation of four sets of genes having 'target genes' . 5a) . Therefore, 54 (41 + 13) selected terms were implied to find their links with candidate genes in subsequent analysis. Total 40 functional annotation terms had been found for 21 'candidate genes' represented in the checkerboard diagram (Fig. 5c) Fig. 3b and Fig. 3c ). . 5d) . Interestingly, certain pair-wise terms appeared common among statistically significant terms under (a) enriched for 'candidate genes' (Fig. 5d) and (b) 'target nodes' for symptoms/diseases under TN (Fig. 3a) and, found to have greater pair-wise SSS-II values with 'candidate genes' viz. atrophy-aphasia (3.7% more SSS-II value) as symptom-pair ( Fig. 3b and Fig. 5d ) and other five disease-pairs including (a) 'progressive non-fluent aphasia' with 'classic progressive supranuclear palsy syndrome' (15% more SSS-II value), 'amyotrophic lateral sclerosis' (32.5% more SSS-II value), 'frontotemporal dementia' (17.7% more SSS-II value) and (b) 'frontotemporal dementia' with 'amyotrophic lateral sclerosis' (8.6% more SSS-II value) and 'progressive supranuclear palsy syndrome' (17.2% more SSS-II value) ( Fig. 3c and Fig. 5d ). Cross-validation through leave-one-out method of 21 candidate-gene from the 281 gene node containing CGN network resulted 3.15% average reduction in 'both HB and driver' node and average increase in 7.96% and 4.81% 'pure driver' and 'driver' nodes, respectively (Fig. 5e) . The results signified that the 21 'candidate genes' appeared to be 'indispensable' driver nodes and supposed to be COVID-19 predictive neurological disease-related regulatory genes. The 21 'candidate genes', their 21 interactions having WHMS and links with corresponding functional annotations had been integrated in pictorial diagram (Fig. 5f) (Fig. 5f ). The present study is a novel approach of combined meta-analysis of two networks viz. TN and CGN to find the 'disease-related regulatory genes' associated with functional In the present study, two networks (TN (Fig. 3a) and CGN (Fig. 4b) ) were analyzed to find the 'target nodes' which satisfied the three properties viz. 'hub', 'bottlenecks' and 'driver' together for COVID-19. Separate studies indicates that host proteins targeted by viral proteins show the node properties of hubs and high betweenness centrality 82 i.e., together hub and bottlenecks), driver and both (HB and driver) ( Fig. 3d and Fig. 3e ). All 'target genes' (TG) evaluated from CGN (TG-CGN) showed node properties as both HB and driver ( Fig. 4b and Fig. 4c ). In fact, the number of driver nodes compared to the driver nodes themselves appears as crucial for maintenance the controllability of a network 69, 71 . In the present study, the finally selected 21 'candidate genes' appeared as 'indispensable' as the number of driver nodes increased (4.81% for total driver, 7.96% for driver but non-hub-bottlenecks i.e., pure driver) in the CGN after removal of one of the 'candidate genes' (Fig. 5e) . The SPPICS were applied to construct possible PPI connections of new genes in TN ( genes for a disease show common biological pathway(s) 48 . Therefore, in the present study, the functional association among 'target nodes' were analyzed by semantic comparison of GO-BP annotations quantitatively through computing similarities between gene-pairs (SSS-I measurement) (Fig. 3d and Fig. 4d ) and also clustering gene/symptoms/disease/module-pairs (SSS-II measurement) into known pathways (Fig. 3b, Fig. 3c, Fig. 3e, Fig. 4e and Fig. 5d ). The conventional SSS-I provided pair-wise 'direct association' based on comparative assessment of associated GO-BP terms of two target genes ( Fig. 3d and Fig. 4d ). It is reported that the genes and their functionally connected co-expressive genes show tissue specific expressions and regulations (transcriptional and translational) and, exhibit pleotropic effects i.e., share common symptoms and diseases [86] [87] [88] [89] . Based on this concept, the estimation of SSS-II values was newly introduced in the present study ( Fig. 3e and functional relationship by sharing common GO-BP annotation terms to reflect the discrete or pleotropic effects of genes among networks (Table 1) . Particularly, the zero value of SSS-II of a gene-pair indicated that 'gene-clusters' (connected genes) against the genepair did not well-supported by current literature-based evidences related to COVID-19 neurological symptoms. Therefore, the SSS-II values might provide a better diseasespecific metric for the event of disassembly in the homeostatic genetic connectivity that being perturbed during COVID-19 insult. The increased network quality enhances the prediction accuracy of finding 'candidate genes' for a disease in PPI network-based model. The PPI model of STRING-database includes genes from prior knowledge and therefore has its own limitation 56 Fig. 5f ) having integrated scores provided excellently strong fitted (AUC>0.9) and most accurate (95%) interactions (Fig. 5b) for prediction of 21 'candidate genes' (Fig. 5c and Fig. 5f ) involved in neurological insults (Fig. 5f ) in COVID- All 21 gene-pairs/PPIs of 'candidate genes' showed SSS-I values (Fig. 3d, Fig. 4d , vide were classified as 'prevalent' and 'non-prevalent' 'candidate genes' (Table 1 ). Six pairs of seven 'prevalent' 'candidate genes' showed strong database-dependent putative interaction scores (SPPICS) (Fig. 3a and Fig. 4b ) and subsequently satisfied SSS-II values ( Fig. 3e and Fig. 4e ) above the threshold levels representing 'is_a' relationship (Table 1) with neuro-pathological manifestations in COVID-19. The 'non-prevalent' 'candidate genes' found to have varied SPPICS scores (strong and weak) and different relationships ('is_a' and 'part-of') among their gene-pairs ( Table 1 ). The 'prevalent' Notably, two prevalent genes CTNNB1 and AKT1 appeared to be common for both TN ( Fig. 3a) and CGN (Fig. 4b) . Both genes showed SSS-II (network specific semantic similarity score) values greater than threshold values in respective cases ( Fig. 3e and Fig. 4e ) and therefore functionally interlinked (Fig. 5f ). CTNNB1 appeared as the lone gene having both HB and diver node properties in TN. Interestingly, CTNNB1 was the only gene which formed a 'tripartite open network' that linked with eight symptoms and those symptoms remained connected with eight diseases (Fig. 3a) . The terms 'Is_a' and 'Part_of'' properties are considered to the gene-pairs with scores greater than and less than cut-off values of SSS-I and SSS-II respectively. The terms 'Strong' and 'Weak' represent the link strength having values of SPPICS to gene-pairs with scores greater than and less than cut-off value respectively. The cut-off values (optimal threshold score of ROC) are given in Fig. 5B . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures Clinical features of patients infected with 2019 novel coronavirus in Wuhan A Novel Coronavirus from Patients with Pneumonia in China A novel coronavirus outbreak of global health concern World Health Organization SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids Neurological associations of COVID-19 Neurological infection with SARS-CoV-2 -the story so far Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia Inflammatory Response Leads to Neuronal Death in Human Post-Mortem Cerebral Cortex in Patients with COVID-19 COVID-19 and olfactory dysfunction: A possible associative approach towards neurodegenerative diseases Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside Presentations and mechanisms of CNS disorders related to COVID-19 Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Characteristics of ischaemic stroke associated with COVID-19 A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 Neurologic Features in Severe SARS-CoV-2 Infection COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study COVID-19-associated ophthalmoparesis and hypothalamic involvement Acute myelitis as a neurological complication of Covid-19: a case report and MRI findings Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients Neurological manifestations in COVID-19: a systematic review and meta-analysis Neurological manifestations of COVID-19: available evidences and a new paradigm Neurological Manifestations in COVID-19 Infection: A Systematic Review and Meta-Analysis Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions Neurological manifestations of COVID-19: a systematic review Neurological Manifestations in COVID-19 Patients: A Meta-Analysis Critical illness myopathy after COVID-19 Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Brain Disease Network Analysis to Elucidate the Neurological Manifestations of COVID-19 Endocrine disrupting chemicals and COVID-19 relationships: A computational systems biology approach The multiplex network of human diseases A Computational-Based Drug Repurposing Method Targeting SARS-CoV-2 and its Neurological Manifestations Genes and Signaling Pathways PRISMA Group Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement The Human Phenotype Ontology in 2021 Bibliometric Keyword Analysis across Seventeen Years (2000-2016) of Intelligence Articles MultiSourcDSim: an integrated approach for exploring disease similarity MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search Human symptoms-disease network The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets Cytoscape: a software environment for integrated models of biomolecular interaction networks Analyzing biological network parameters with CentiScaPe Detection of SARS-CoV-2 genome and whole transcriptome sequencing in frontal cortex of COVID-19 patients A gene recommender algorithm to identify coexpressed genes in C. elegans geneRecommender: A gene recommender algorithm to identify genes coexpressed with a query set of genes minet: A R/Bioconductor Package for Inferring Large Transcriptional Networks Using Mutual Information ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context Evidence for dynamically organized modularity in the yeast protein-protein interaction network High-quality binary protein interaction map of the yeast interactome network Revisiting date and party hubs: novel approaches to role assignment in protein interaction networks Dynamic modular architecture of protein-protein interaction networks beyond the dichotomy of 'date' and 'party' hubs CytoCtrlAnalyser: a Cytoscape app for biomolecular network controllability analysis Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets Controllability of complex networks Network controllability analysis of intracellular signalling reveals viruses are actively controlling molecular systems Systems biology and the future of medicine Ontologies in biology: design, applications and future challenges Use and misuse of the gene ontology annotations GOSemSim: an R package for measuring semantic similarity among GO terms and gene products A new method to measure the semantic similarity of GO terms Semantic similarity in biomedical ontologies pROC: an open-source package for R and S+ to analyze and compare ROC curves Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool Integration of anatomy ontology data with proteinprotein interaction networks improves the candidate gene prediction accuracy for anatomical entities Beyond degree and betweenness centrality: Alternative topological measures to predict viral targets The Gene Ontology (GO) database and informatics resource Identifying term relations cross different gene ontology categories Biological feature selection and disease gene identification using new stepwise random forests Network properties of human disease genes with pleiotropic effects The human disease network A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes Gene coexpression analysis for functional classification and gene-disease predictions Recent advances in clustering methods for protein interaction networks Shedding light on COVID-19: ADAM17 the missing link? The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer's Disease ADAM17 participates in the protective effect of paeoniflorin on mouse brain microvascular endothelial cells Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19 Integrated Genome-Wide DNA Methylation and RNAseq Analysis of Hippocampal Specimens Identifies Potential Candidate Genes and Aberrant Signalling Pathways in Patients with Hippocampal Sclerosis Biologia Futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients? Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer Genome-Wide Screen Reveals Valosin-Containing Protein Requirement for Coronavirus Exit from Endosomes Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment The DNA repair protein ATM as a target in autism spectrum disorder Bioinformatics analyses of significant genes, related pathways, and candidate diagnostic biomarkers and molecular targets in SARS-CoV-2/COVID-19 BDNF-GSK-3β-β-Catenin Pathway in the mPFC Is Involved in Antidepressant-Like Effects of Morinda officinalis Oligosaccharides in Rats Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools Nervous system involvement after infection with COVID-19 and other coronaviruses Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death Gene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis Induction of the Wnt antagonist Dickkopf-1 is involved in stress-induced hippocampal damage Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis GLI2 Is a Regulator of β-Catenin and Is Associated with Loss of E-Cadherin, Cell Invasiveness, and Long-Term Epidermal Regeneration Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features MLL2 gene variants and risk of childhood medulloblastoma Aromatase promoter I.f is regulated by estrogen receptor alpha (ESR1) in mouse hypothalamic neuronal cell lines BARHL1 Is Downregulated in Alzheimer's Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer Estrogen Hormone Is an Essential Sex Factor Inhibiting Inflammation and Immune Response in COVID-19 The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages Mutational Spectrum in Holoprosencephaly Shows That FGF is a New Major Signaling Pathway Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations All the Bioinformatic, statistical, formal and software analysis related to research data were performed by A. G. C. reviewed and edited the draft and all authors gave consent to publish the data presented in the article. The project study was administered by both corresponding authors N. C We thank Department of Biotechnology ( The authors declare that they have no competing interests. All data are available in the paper.